CN102050815B - 作为前药的达比加群的酯衍生物 - Google Patents
作为前药的达比加群的酯衍生物 Download PDFInfo
- Publication number
- CN102050815B CN102050815B CN200910211165.2A CN200910211165A CN102050815B CN 102050815 B CN102050815 B CN 102050815B CN 200910211165 A CN200910211165 A CN 200910211165A CN 102050815 B CN102050815 B CN 102050815B
- Authority
- CN
- China
- Prior art keywords
- methyl
- dabigatran
- amino
- ester
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960003850 dabigatran Drugs 0.000 title claims abstract description 48
- -1 Dabigatran ester Chemical class 0.000 title abstract description 35
- 229940002612 prodrug Drugs 0.000 title description 2
- 239000000651 prodrug Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 7
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 7
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 41
- 150000002148 esters Chemical class 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 abstract description 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000002131 composite material Substances 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 42
- 238000000034 method Methods 0.000 description 38
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000543 intermediate Substances 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 18
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 14
- 238000010511 deprotection reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 229940000635 beta-alanine Drugs 0.000 description 10
- BGLLICFSSKPUMR-UHFFFAOYSA-N ethyl 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate Chemical compound C=1C=CC=NC=1N(CCC(=O)OCC)C(=O)C(C=C1N=2)=CC=C1N(C)C=2CNC1=CC=C(C(N)=N)C=C1 BGLLICFSSKPUMR-UHFFFAOYSA-N 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229960000288 dabigatran etexilate Drugs 0.000 description 5
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 5
- 231100000956 nontoxicity Toxicity 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 3
- FRKPLOTVTBSTPB-UHFFFAOYSA-N ClS(=O)(=O)O.ClC(=O)O Chemical class ClS(=O)(=O)O.ClC(=O)O FRKPLOTVTBSTPB-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- VRIGUKQJHAWXGW-IUCAKERBSA-N chloromethyl (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound ClCOC(=O)[C@H]([C@@H](C)CC)NC(=O)OC(C)(C)C VRIGUKQJHAWXGW-IUCAKERBSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- FTINTRPSAYYLMB-UHFFFAOYSA-N 2-amino-4-methyl-3-nitrobenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1[N+]([O-])=O FTINTRPSAYYLMB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- JPOXNPPZZKNXOV-UHFFFAOYSA-N bromochloromethane Chemical compound ClCBr JPOXNPPZZKNXOV-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- UITNIDFEANEWPC-UHFFFAOYSA-N ethyl 3-(pyridin-2-ylamino)propanoate Chemical compound CCOC(=O)CCNC1=CC=CC=N1 UITNIDFEANEWPC-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
- MLRVZFYXUZQSRU-UHFFFAOYSA-N 1-chlorohexane Chemical compound CCCCCCCl MLRVZFYXUZQSRU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- PJBIHXWYDMFGCV-UHFFFAOYSA-N chloro(chlorosulfonyloxy)methane Chemical class ClCOS(Cl)(=O)=O PJBIHXWYDMFGCV-UHFFFAOYSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- ZDVSSXVVRYYLKC-LBPRGKRZSA-N chloromethyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OCCl)CC1=CC=CC=C1 ZDVSSXVVRYYLKC-LBPRGKRZSA-N 0.000 description 1
- ILUWVORABZTBIU-UHFFFAOYSA-N chloromethyl 2-methylpropanoate Chemical compound CC(C)C(=O)OCCl ILUWVORABZTBIU-UHFFFAOYSA-N 0.000 description 1
- HOFHLRCDGWSLHX-UHFFFAOYSA-N clamoxyquine Chemical compound C1=CC=NC2=C(O)C(CNCCCN(CC)CC)=CC(Cl)=C21 HOFHLRCDGWSLHX-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
技术领域
本发明涉及新的达比加群的酯衍生物及其非毒性药学上可接受的盐,以及含有这些化合物作为活性成分的药物组合物,以及所述化合物及药物组合物作为凝血酶抑制剂的用途。
背景技术
达比加群(Dabigatran)是一种选择性的高效凝血酶抑制剂。但是由于强碱性脒基的存在,口服不能吸收。为提高其生物利用度,分别将达比加群分子中的游离羧基成乙酯,脒基成氨基甲酸己酯,得到其双前体药物达比加群双酯(Dabigatran Etexilate)。达比加群双酯口服后,从胃肠道吸收,然后在体内转化为活性形式的达比加群,发挥抗凝血作用。达比加群双酯于2008年上市,成为首个口服凝血酶抑制剂,用于预防人工关节置换术后并发深静脉血栓形成和肺动脉栓塞。但是,达比加群双酯的口服生物利用度(6.5%)仍有待进一步提高。
达比加群 达比加群双酯
发明内容
本发明涉及由结构式I所示的达比加群的酯衍生物及其非毒性药学上可接受的盐,以及含有这些化合物作为活性成分的药物组合物,以及所述化合物及药物组合物作为凝血酶抑制剂的用途。
因此,本发明的第一个方面提供了式I所代表的达比加群的酯衍生物及其可药用盐:
其中,
R1代表H或C1-C5的烷基;R2代表H,或C1-C3的烷基;
R3代表C1-C8的烷基或取代烷基。
优选地,本发明提供式I所代表的达比加群的酯衍生物或其可药用盐,其中R1代表C1-C5的烷基,R2代表H或C1-C3的烷基,R3代表C1-C8的烷基。
更优选地,本发明提供式I所代表的达比加群的酯衍生物或其可药用盐,其中R1代表C1-C5的烷基,R2代表H,R3代表α-位为氨基取代的烷基或芳香烷基。
更优选地,本发明提供式I所代表的达比加群的酯衍生物或其可药用盐选自如下结构式所代表的化合物:
具体目标化合物的各取代基分别定义如下:
I1:R1为-CH3,R2为H,R3为-CH3;
I2:R1为-CH3,R2为H,R3为-CH2CH3;
I3:R1为-CH3,R2为H,R3为-CH2CH2CH3;
I4:R1为-CH3,R2为H,R3为-CH(CH3)2;
I5:R1为-CH3,R2为H,R3为-C(CH3)3;
I6:R1为-CH3,R2为H,R3为-CH(CH3)CH2CH3;
I7:R1为-CH3,R2为H,R3为-CH2CH(CH3)CH3;
I8:R1为-CH3,R2为H,R3为-CH2CH2CH2CH3;
I9:R1为-CH3,R2为H,R3为-CH2CH2CH2CH2CH3;
I10:R1为-CH3,R2为H,R3为-CH2NH2;
I11:R1为-CH3,R2为H,R3为-CH(NH2)CH3;
I12:R1为-CH3,R2为H,R3为-CH(NH2)CH2CH(CH3)2;
I13:R1为-CH3,R2为H,R3为-CH(NH2)CH(CH3)CH2CH3;
I14:R1为-CH3,R2为H,R3为-CH(NH2)CH(CH3)2;
I15:R1为-CH3,R2为H,R3为-CH(NH2)CH2Ph;
I17:R1为-CH2CH3,R2为H,R3为-CH3;
I18:R1为-CH2CH3,R2为H,R3为-CH2CH3;
I19:R1为-CH2CH3,R2为H,R3为-CH2CH2CH3;
I20:R1为-CH2CH3,R2为H,R3为-CH(CH3)2;
I21:R1为-CH2CH3,R2为H,R3为-C(CH3)3;
I22:R1为-CH2CH3,R2为H,R3为-CH(CH3)CH2CH3;
I23:R1为-CH2CH3,R2为H,R3为-CH2CH(CH3)CH3;
I24:R1为-CH2CH3,R2为H,R3为-CH2CH2CH2CH3;
I25:R1为-CH2CH3,R2为H,R3为-CH2CH2CH2CH2CH3;
I26:R1为-CH2CH3,R2为H,R3为-CH2NH2;
I27:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH3;
I28:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH2CH(CH3)2;
I29:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)CH2CH3;
I30:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)2;
I31:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH2Ph;
I33:R1为-CH2CH2CH3,R2为H,R3为-CH3;
I34:R1为-CH2CH2CH3,R2为H,R3为-CH2CH3;
I35:R1为-CH2CH2CH3,R2为H,R3为-CH2CH2CH3;
I36:R1为-CH2CH2CH3,R2为H,R3为-CH(CH3)2;
I37:R1为-CH2CH2CH3,R2为H,R3为-C(CH3)3;
I38:R1为-CH2CH2CH3,R2为H,R3为-CH(CH3)CH2CH3;
I39:R1为-CH2CH2CH3,R2为H,R3为-CH2CH(CH3)CH3;
I40:R1为-CH2CH2CH3,R2为H,R3为-CH2CH2CH2CH3;
I41:R1为-CH2CH2CH3,R2为H,R3为-CH2CH2CH2CH2CH3;
I42:R1为-CH2CH2CH3,R2为H,R3为-CH2NH2;
I43:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH3;
I44:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH2CH(CH3)2;
I45:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)CH2CH3;
I46:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)2;
I47:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH2Ph;
I49:R1为-CH3,R2为CH3,R3为-CH3;
I50:R1为-CH3,R2为CH3,R3为-CH2CH3;
I51:R1为-CH3,R2为CH3,R3为-CH2CH2CH3;
I52:R1为-CH3,R2为CH3,R3为-CH(CH3)2;
I53:R1为-CH3,R2为CH3,R3为-C(CH3)3;
I54:R1为-CH3,R2为CH3,R3为-CH(CH3)CH2CH3;
I55:R1为-CH3,R2为CH3,R3为-CH2CH(CH3)CH3;
I56:R1为-CH3,R2为CH3,R3为-CH2CH2CH2CH3;
I57:R1为-CH3,R2为CH3,R3为-CH2CH2CH2CH2CH3;
I58:R1为-CH2CH3,R2为CH3,R3为-CH3;
I66:R1为-CH2CH3,R2为CH3,R3为-CH2CH3;
I67:R1为-CH2CH3,R2为CH3,R3为-CH2CH2CH3;
I68:R1为-CH2CH3,R2为CH3,R3为-CH(CH3)2;
I69:R1为-CH2CH3,R2为CH3,R3为-C(CH3)3;
I70:R1为-CH2CH3,R2为CH3,R3为-CH(CH3)CH2CH3;
I71:R1为-CH2CH3,R2为CH3,R3为-CH2CH(CH3)CH3;
I72:R1为-CH2CH3,R2为CH3,R3为-CH2CH2CH2CH3;
I73:R1为-CH2CH3,R2为CH3,R3为-CH2CH2CH2CH2CH3;
I74:R1为-CH2CH2CH3,R2为CH3,R3为-CH3;
I75:R1为-CH2CH2CH3,R2为CH3,R3为-CH2CH3;
I76:R1为-CH2CH2CH3,R2为CH3,R3为-CH2CH2CH3;
I77:R1为-CH2CH2CH3,R2为CH3,R3为-CH(CH3)2;
I78:R1为-CH2CH2CH3,R2为CH3,R3为-C(CH3)3;
I79:R1为-CH2CH2CH3,R2为CH3,R3为-CH(CH3)CH2CH3;
I80:R1为-CH2CH2CH3,R2为CH3,R3为-CH2CH(CH3)CH3;
I81:R1为-CH2CH2CH3,R2为CH3,R3为-CH2CH2CH2CH3;
I82:R1为-CH2CH2CH3,R2为CH3,R3为-CH2CH2CH2CH2CH3。
本发明的第二个方面涉及药物组合物,其包括至少一种式I所代表的达比加群的酯衍生物及其可药用盐以及一种或多种药学上可接受的载体或赋形剂。
本发明的第三个方面涉及式I所示的达比加群的酯衍生物及其非毒性药学上可接受的盐,以及包含式I所示的达比加群的酯衍生物及其非毒性药学上可接受的盐作为活性成分的药物组合物作为抗凝药的用途。
式I所代表的化合物可以与无机酸形成药用盐,例如硫酸盐、盐酸盐、氢溴酸盐、磷酸盐;也可与有机酸形成药用盐,例如乙酸盐、草酸盐、柠檬酸盐、葡萄糖酸盐、琥珀酸盐、酒石酸盐、对甲苯磺酸盐、甲磺酸盐、苯甲酸盐、乳酸盐、马来酸盐等。选择和制备适当的盐是本领域技术人员公知技术。
本发明化合物或其可药用盐可以形成溶剂化物,例如水合物、醇合物等;选择和制备适当的溶剂化物是本领域技术人员公知技术。
本发明化合物或其可药用盐可以单独或以药物组合物的形式给药。本发明药物组合物可根据给药途径配成各种适宜的剂型。使用一种或多种生理学上可接受的载体,包含赋形剂和助剂,它们有利于将活性化合物加工成可以在药学上使用的制剂。适当的制剂形式取决于所选择的给药途径,可以按照本领域熟知的常识进行制造。
给药途径可以是口服、非肠道或局部给药,优选口服和注射形式给药。可以口服的药物制剂包括胶囊剂和片剂等。病人吞咽有困难时,也可以采用舌下片或者其他非吞咽的方式给药。本发明化合物也可以配制用于肠胃外给药或者透皮给药或者经粘膜给药。或者采用栓剂或者埋植剂的方式给药。本领域技术人员可以理解,本发明化合物可以采用合适的药物释放系统(DDS)以得到更有利的效果。
另外需要指出,本发明化合物使用剂量和使用方法取决于诸多因素,包括患者的年龄、体重、性别、自然健康状况、营养状况、化合物的活性强度、服用时间、代谢速率、病症的严重程度以及诊治医师的主观判断。
具体实施方式
下面的实施例可以对本发明进行进一步的描述,然而,这些实施例不应作为对本发明的范围的限制。
首先,参照文献(Hauel NH,Nar H,Priepke H,et al.Structure-Based Designof Novel Potent Nonpeptide Thrombin Inhibitors.J.Med.Chem.2002;45:1757-1766)方法合成达比加群双酯(Dabigatran Etexilate)及式II所示的达比加群的乙酯衍生物:
R1=-CH3,-(CH2)2CH3,-(CH2)3CH3,或-(CH2)4CH3
以3-硝基-4-甲基氨基-苯甲酸为起始原料,与氯化亚砜反应,成酰氯(中间体2);中间体2与N-(吡啶-2-基)-β-丙氨酸乙酯反应,得到中间体4;将中间体4的硝基在钯-炭作用下,催化氢化得到中间体5;(4-氰基-苯基氨基)乙酸先与羰基二咪唑反应,再与中间体5反应,得到中间体7;将中间体7与氯化氢反应,然后用碳酸铵碱化,得到达比加群的乙酯衍生物(II1),II1与氯甲酸己酯反应,得到达比加群双酯(Dabigatran Etexilate);中间体7与氢氧化钠反应,水解得到羧酸钠衍生物(中间体8);中间体8与卤代烷反应,得到酯衍生物(中间体9);中间体9与氯化氢反应,得到达比加群的羧酸酯衍生物II2-5)。
参考实施例1 N-{[2-(((4-脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(II1)的制备
将40克(0.2mol)3-硝基-4-甲基氨基-苯甲酸加于400mL氯化亚砜中,加入0.2mL二甲基甲酰胺,回流反应0.5h,真空浓缩,得到3-硝基-4-甲基氨基-苯甲酰氯(中间体2),溶于300mL四氢呋喃。
将37克(0.2mol)N-(吡啶-2-基)-β-丙氨酸乙酯和60mL三乙胺溶于500mL四氢呋喃中,在室温下滴加中间体2的四氢呋喃溶液。加完后,室温反应过夜,真空浓缩。将残留物用硅胶柱层析分离,用二氯甲烷∶乙醇(99∶1)的混合溶剂洗脱,得到41克中间体4。
将33.4克(89.4mmol)中间体4溶于400mL乙醇,加入10%的钯-炭1克,室温氢化,过滤除去钯-炭,将滤液真空浓缩。将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(30∶1)的混合溶剂洗脱,得到21克中间体5。
将12.8g(73mmol)(4-氰基-苯基氨基)乙酸和11.8克(73mmol)羰基二咪唑加于300mL四氢呋喃中,50℃搅拌反应30min。然后,向此溶液中加入21克中间体5,回流反应24h。真空浓缩,将残留物溶于150mL冰乙酸中,加热回流1h,将此溶液用500mL水稀释,用浓氨水中和。用乙酸乙酯提取,将提取液真空浓缩。将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(40∶1)的混 合溶剂洗脱,得到18克N-{[2-(((4-氰基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(中间体7)。
将18克中间体7溶于800mL乙醇中,冷却到0℃,通无水氯化氢气体2h,然后室温搅拌5h。将溶剂真空蒸干,然后将残留物溶于600mL乙醇,加入40克碳酸铵,室温搅拌过夜。将反应液真空浓缩,将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(5∶1)的混合溶剂洗脱,得到14克目标化合物II1。1H NMRδ(ppm,DMSO-d6):1.14(t,3H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.24(t,2H),4.68(d,2H),6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,3H)。
参考实施例2 N-{[2-(((4-脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(II2)的制备
将5克中间体7溶于200mL乙醇中,加入1N的NaOH溶液10.4mL,室温下搅拌反应至水解完全;然后真空蒸干,以20mL二甲基甲酰胺溶解,加入1.76克碘甲烷,室温搅拌24h,真空浓缩,将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(40∶1)的混合溶剂洗脱,得到3.9克N-{[2-(((4-氰基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(中间体9a)。
将3.9克中间体9a溶于100mL乙醇中,冷却到0℃,通无水氯化氢气体2h,然后室温搅拌5h。将溶剂真空蒸干,然后将残留物溶于100mL乙醇,加入10克碳酸铵,室温搅拌过夜。将反应液真空浓缩,将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(5∶1)的混合溶剂洗脱,得到2.7克目标化合物II2。1H NMRδ(ppm,DMSO-d6):2.68(t,2H),3.79(s,3H),3.86(s,3H),4.25(t,2H),4.69(d,2H),6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,3H)。
参考实施例3 N-{[2-(((4-脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(II3)的制备
将5克中间体7溶于200mL乙醇中,加入1N的NaOH溶液10.4mL,室温下搅拌反应至水解完全;然后真空蒸干,以20mL二甲基甲酰胺溶解,加入1.53克溴丙烷,在50℃加热搅拌24h,真空浓缩,将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(40∶1)的混合溶剂洗脱,得到3.6克N-{[2-(((4-氰基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(中间体9b)。
将3.6克中间体9b溶于100mL乙醇中,冷却到0℃,通无水氯化氢气体2h,然后室温搅拌5h。将溶剂真空蒸干,然后将残留物溶于100mL乙醇,加入10克碳酸铵,室温搅拌过夜。将反应液真空浓缩,将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(5∶1)的混合溶剂洗脱,得到2.6克目标化合物II3。1H NMRδ(ppm,DMSO-d6):0.92(t,3H),1.29(m,2H),2.68(t,2H),3.78(s,3H),4.02(t,2H),4.23(t,2H),4.67(d,2H),6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(dt,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,3H)。
参考实施例4 N-{[2-(((4-N-己氧羰基-脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(达比加群双酯)的制备
将2.0g(3.72mmol)N-{[2-(((4-脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(II1)溶于100mL四氢呋喃和20mL水的混和溶剂中,加入1.66g碳酸钾(12mmol),室温搅拌20min。加入0.62g(3.72mmol)正-己基氯甲酸酯,继续搅拌2h。真空蒸除溶剂,加入100ml饱和盐水,用二氯甲烷提取3次,40ml/次;合并提取液,用无水硫酸钠干燥;真空蒸除溶剂,将残留物用硅胶柱层析分离,用二氯甲烷∶乙醇(95∶5)洗脱,得到目标化合物1.4g,mp 128-130℃。1H NMRδ(ppm,DMSO-d6):0.89(t,3H),1.16(t,3H),1.31(m,6H),1.60(m,2H),2.71(t,2H),3.79(s,3H),3.98(m, 4H),4.25(t,2H),4.62(d,2H),6.75(d,2H),6.90(d,1H),6.97(t,1H),7.14(m,2H),7.41(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.41(dd,1H),8.50-9.30(bs,2H)。
当R3为C1-C8的烷基时,目标化合物的合成路线如下:
达比加群的羧酸酯衍生物II与羧酸氯甲酯III反应,即得到目标化合物。
实施例1 N-{[2-(((4-(N-丙酰氧甲基-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I18)的制备
将0.65克(1.3mmol)达比加群乙酯(II1)溶于2mL DMF中,加入0.18克K2CO3(1.3mmol),搅拌下滴加0.15mL(1.3mmol)氯甲基丙酸酯于1mLDMF的溶液,在15min内加完;加完后,将反应混合物于室温搅拌反应20h。将反应液真空浓缩,将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇(5∶1)的混合溶剂洗脱,得到0.48克目标化合物I18。1H NMRδ(ppm,DMSO-d6):1.08(t,3H),1.14(t,3H),2.34(q,2H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.24(t,2H),4.68(d,2H),5.75(s,2H),6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(dt,1H),7.82(d,2H),8.42(dd,1H),8.58-9.30(bs,2H)。
实施例2 N-{[2-(((4-(N-丁酰氧甲基-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯 并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I19)的制备
参照实施例1的方法,用氯甲基-丁酸酯代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得目标化合物I19,产率62%。1H NMRδ(ppm,DMSO-d6):0.85(t,3H),1.14(t,3H),1.51(m,2H),2.28(t,2H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.24(t,2H),4.68(d,2H),5.75(s,2H),6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(dt,1H),7.82(d,2H),8.42(dd,1H),8.58-9.30(bs,2H)。
实施例3 N-{[2-(((4-(N-异丁酰氧甲基-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I20)的制备
参照实施例1的方法,用氯甲基-异丁酸酯代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得目标化合物I20,产率71%。1H NMRδ(ppm,DMSO-d6):1.05(d,6H),1.14(t,3H),2.55(m,1H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.24(t,2H),4.68(d,2H),5.75(s,2H),6.89(m,3H),7.12(m,2H),7.36-7.60(m,4H),7.68(d,2H),8.41(m,1H),8.68(s,2H),8.58-9.30(bs,2H)。
实施例4 N-{[2-(((4-(N-1-(丁酰氧基-)乙基-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I67)的制备
参照实施例1的方法,用1-氯乙基-丁酸酯代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得目标化合物I67,产率68%。1H NMRδ(ppm,DMSO-d6):0.84(t,3H);1.14(t,3H),1.51(m,2H),1.69(d,3H),2.26(t,2H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.24(t,2H),4.68(d,2H),6.67(q,1H),6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(dt,1H),7.82(d,2H),8.42(dd,1H),8.58-9.30(bs,2H)。
当R3代表α-位为氨基取代的烷基或芳香烷基(R3=-CH(NH2)R4)时,目 标化合物的合成路线如下(反应式中,R1代表甲基、乙基或丙基,R4代表氢、甲基、异丙基、异丁基、2-甲基丙基或苯甲基等L-氨基酸的侧链。):
溴氯甲烷与氯磺酸加热回流,得到氯甲基氯磺酸酯IV,IV然后与N-叔丁氧羰基-氨基酸反应,得到N-叔丁氧羰基氨基酸的氯甲基酯V,V与II反应得到中间体VI,VI脱保护得到目标化合物。
实施例5 N-{[2-(((4-(N-(L-甘氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I26)的制 备
5.1 氯甲酸氯磺酸酯(IV)的合成
将100mL氯磺酸与50mL氯甲烷混合,缓慢加热至回流,保持回流反应3h。冷却后,缓慢倒于500克碎冰中。用二氯甲烷提取2次,400mL/次;合并有机层,用无水硫酸钠干燥;滤去干燥剂,蒸除溶剂,然后将残余物减压分馏,收集45-50℃/9-10mmHg的馏分,得产物IV31克。
5.2 N-Boc-L-甘氨酸-氯甲基酯(V1)的合成
将3.5克(0.02mol)N-Boc-L-甘氨酸,6.65克碳酸氢钠及0.68克四-正丁基硫酸氢铵(0.002mol)加于80ml水与80ml二氯甲烷的混合溶剂中,冰盐浴冷却至O℃,剧烈搅拌下缓慢滴加入4克氯甲基氯磺酸酯于18ml二氯甲烷的溶液;加完后,升至室温,继续搅拌反应12小时。将有机层分出,以饱和食盐水洗2次,15ml/次;将有机层用无水硫酸钠干燥,滤除干燥剂,将滤液减压浓缩,残留物用硅胶柱层析分离,用石油醚∶乙酸乙酯(15∶1)洗脱,得V1的无色油状物3.2克。
5.3 N-{[2-(((4-(N-(N-Boc-L-甘氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(VI1)的制备
参照实施例1的方法,用N-Boc-L-甘氨酸-氯甲基酯(V1)代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得VI1,产率68%。
5.4 N-{[2-(((4-(N-(L-甘氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I26)的制备
将2.0克VI1用10ml干燥的1,4-二氧六环溶解,氮气保护下用冰盐浴冷却至0℃,搅拌下缓慢滴加5ml含15%氯化氢的1,4-二氧六环溶液,在0℃搅拌反应1小时,再于室温反应3小时。过滤,用乙醚洗涤,得I26 1.39g。核磁共振氢谱δ(ppm,DMSO-d6):1.14(t,3H),2.69(t,2H),3.78(s,3H),3.85(s,2H), 3.99(q,2H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例 6N-{[2-(((4-(N-(L-丙氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I27)的制备
参照实施例5.2的方法,用N-Boc-L-丙氨酸代替N-Boc-L-甘氨酸,与氯甲基氯磺酸酯(IV)反应,制得N-Boc-L-丙氨酸-氯甲基酯(V2),产率57%。
参照实施例1的方法,用V2代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得N-{[2-(((4-(N-(N-Boc-L-丙氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(VI2),产率52%。
参照实施例5.4的方法,将VI2脱保护,得到目标化合物I27,产率79%。核磁共振氢谱δ(ppm,DMSO-d6):1.14(t,3H),1.52(d,3H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.24(t,2H),4.35(q,1H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例7 N-{[2-(((4-(N-(-L-亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I28)的制备
参照实施例5.2的方法,用N-Boc-L-亮氨酸代替N-Boc-L-甘氨酸,与氯甲基氯磺酸酯(IV)反应,制得N-Boc-L-亮氨酸-氯甲基酯(V3),产率59%。
参照实施例1的方法,用V 3代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得N-{[2-(((4-(N-(N-Boc-L-亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(VI3),产率47%。
参照实施例5.4的方法,将VI3脱保护,得到目标化合物I28,产率81%。核磁共振氢谱δ(ppm,DMSO-d6):0.92(d,6H),1.14(t,3H),1.39(m,1H),2.01(q,2H),2.69(t,2H),3.78(s,3H),3.92(t,1H),3.99(q,2H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例8 N-{[2-(((4-(N-(L-异亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I29)的制备
参照实施例5.2的方法,用N-Boc-L-异亮氨酸代替N-Boc-L-甘氨酸,与氯甲基氯磺酸酯(IV)反应,制得N-Boc-L-异亮氨酸-氯甲基酯(V4),产率50%。
参照实施例1的方法,用V 4代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得N-{[2-(((4-(N-(N-Boc-L-异亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯VI4),产率61%。
参照实施例5.4的方法,将VI4脱保护,得到目标化合物I29,产率82%。核磁共振氢谱δ(ppm,DMSO-d6):0.95(t,3H),0.98(d,3H),1.14(t,3H),1.24(m,2H),2.19(m,1H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.21(d,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例9 N-{[2-(((4-(N-(L-缬氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I30)的制备
参照实施例5.2的方法,用N-Boc-L-缬氨酸代替N-Boc-L-甘氨酸,与氯甲基氯磺酸酯(IV)反应,制得N-Boc-L-缬氨酸-氯甲基酯(V5),产率54%。
参照实施例1的方法,用V 5代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得N-{[2-(((4-(N-(N-Boc-L-缬氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(VI5),产率49%。
参照实施例5.4的方法,将VI5脱保护,得到目标化合物I30,产率85%。核磁共振氢谱δ(ppm,DMSO-d6):0.96(d,6H),1.14(t,3H),2.32(m,1H),2.69(t,2H),3.78(s,3H),3.99(q,2H),4.20(d,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例10 N-{[2-(((4-(N-(L-苯丙氨酰氧甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(I31)的制备
参照实施例5.2的方法,用N-Boc-L-苯丙氨酸代替N-Boc-L-甘氨酸,与氯甲基氯磺酸酯(IV)反应,制得N-Boc-L-苯丙氨酸-氯甲基酯(V6),产率58%。
参照实施例1的方法,用V 6代替氯甲基丙酸酯与达比加群乙酯(II1)反应,制得N-{[2-(((4-(N-(N-Boc-L-苯丙氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸乙酯(VI6),产率46%。
参照实施例5.4的方法,将VI6脱保护,得到目标化合物I31,产率77%。核磁共振氢谱δ(ppm,DMSO-d6):1.14(t,3H),2.69(t,2H),3.13(d,2H),3.78(s,3H),3.99(q,2H),4.22(t,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.11-7.30(m,7H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例11 N-{[2-(((4-(N-异丁酰酰氧甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(I4)的制 备
参照实施例1的方法,用异丁酰氯甲基酯(V2)与达比加群甲酯(II2)反应,制得目标化合物I4,产率55%。核磁共振氢谱1H NMRδ(ppm,DMSO-d6):1.03(d,6H),2.52(m,1H),2.68(t,2H),3.76(s,3H),3.86(s,3H),4.24(t,2H),4.67(d,2H),5.73(s,2H),6.88(m,3H),7.10(m,2H),7.36-7.60(m,4H),7.68(d,2H),8.41(m,1H),8.68(s,2H),8.58-9.30(bs,2H)。
实施例12 N-{[2-(((4-(N-(L-丙氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(I11)的制备
参照实施例1的方法,用N-Boc-L-丙氨酸-氯甲基酯(V2)与达比加群甲酯(II2)反应,制得N-{[2-(((4-(N-(N-Boc-L-丙氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(VI7),产率52%。
参照实施例5.4的方法,将VI7脱保护,得到目标化合物I11,产率79%。核磁共振氢谱δ(ppm,DMSO-d6)1.52(d,3H),2.69(t,2H),3.78(s,3H),3.89(s,3H),4.24(t,2H),4.35(q,1H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(
实施例13 N-{[2-(((4-(N-(L-亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(I12)的制备
参照实施例1的方法,用N-Boc-L-亮氨酸-氯甲基酯(V3)与达比加群甲酯(II2)反应,制得N-{[2-(((4-(N-(N-Boc-L-亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(VI 8),产率47%。
参照实施例5.4的方法,将VI8脱保护,得到目标化合物I12,产率81%。核磁共振氢谱δ(ppm,DMSO-d6):0.92(d,6H),1.39(m,1H),2.01(q,2H),2.69(t,2H),3.78(s,3H),3.88(s,3H),3.92(t,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例14 N-{[2-(((4-(N-(L-异亮氨酰氧甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(I13)的制备
参照实施例1的方法,用N-Boc-L-异亮氨酸-氯甲基酯(V4)与达比加群甲酯(II2)反应,制得N-{[2-(((4-(N-(N-Boc-L-异亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(VI9),产率61%。
参照实施例5.4的方法,将VI9脱保护,得到目标化合物I13,产率82%。核磁共振氢谱δ(ppm,DMSO-d6):0.95(t,3H),0.98(d,3H),1.24(m,2H),2.19(m,1H),2.69(t,2H),3.78(s,3H),3.87(s,3H),4.21(d,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例15 N-{[2-(((4-(N-(L-缬氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(I14)的制备
参照实施例1的方法,用N-Boc-L-缬氨酸-氯甲基酯(V5)与达比加群甲酯(II1)反应,制得目标化合物N-{[2-(((4-(N-(N-Boc-L-缬氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸甲酯(VI10),产率49%。
参照实施例5.4的方法,将VI10脱保护,得到目标化合物I14,产率85%。核磁共振氢谱δ(ppm,DMSO-d6):0.96(d,6H),2.32(m,1H),2.69(t,2H),3.78(s,3H),3.90(s,3H),4.20(d,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例16 N-{[2-(((4-(N-(L-丙氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(I43)的制备
参照实施例1的方法,用N-Boc-L-丙氨酸-氯甲基酯(V2)与达比加群丙酯(II3)反应,制得N-{[2-(((4-(N-(N-Boc-L-丙氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(VI11),产率52%。
参照实施例5.4的方法,将VI11脱保护,得到目标化合物I43,产率79%。核磁共振氢谱δ(ppm,DMSO-d6):0.92(t,3H),1.29(m,2H),1.52(d,3H),2.69(t,2H),3.78(s,3H),4.02(t,2H),4.24(t,2H),4.35(q,1H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例17 N-{[2-(((4-(N-(L-亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(I44)的制备
参照实施例1的方法,用N-Boc-L-亮氨酸-氯甲基酯(V3)与达比加群丙酯(II3)反应,制得N-{[2-(((4-(N-(N-Boc-L-亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(VI 12),产率47%。
参照实施例5.4的方法,将VI12脱保护,得到目标化合物I44,产率81%。核磁共振氢谱δ(ppm,DMSO-d6):0.90-0.92(m,9H),1.29(m,2H),1.39(m,1H),2.01(q,2H),2.69(t,2H),3.78(s,3H),3.92(t,1H),4.02(t,2H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例18 N-{[2-(((4-(N-(L-异亮氨酰氧甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(I45)的制备
参照实施例1的方法,用N-Boc-L-异亮氨酸-氯甲基酯(V4)与达比加群丙酯(II3)反应,制得目标化合物N-{[2-(((4-(N-(N-Boc-L-异亮氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(VI13),产率61%。
参照实施例5.4的方法,将VI13脱保护,得到目标化合物I45,产率82%。核磁共振氢谱δ(ppm,DMSO-d6):0.92(t,3H),0.95(t,3H),0.98(d,3H),1.24(m,2H),1.29(m,2H),2.19(m,1H),2.69(t,2H),3.78(s,3H),4.02(t,2H),4.21(d,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例19 N-{[2-(((4-(N-(L-缬氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙氨酸丙酯(I46)的制备
参照实施例1的方法,用N-Boc-L-缬氨酸-氯甲基酯(V5)与达比加群丙酯(II3)反应,制得目标化合物N-{[2-(((4-(N-(N-Boc-L-缬氨酰氧-甲基)-)脒基-苯基)-氨基)-甲基)-1-甲基-1H-苯并咪唑-5-基]-羰基}-N-(吡啶-2-基)-β-丙 氨酸丙酯(VI14),产率49%。
参照实施例5.4的方法,将VI14脱保护,得到目标化合物I46,产率85%。核磁共振氢谱δ(ppm,DMSO-d6):0.92(t,3H),0.96(d,6H),1.29(m,2H),2.32(m,1H),2.69(t,2H),3.78(s,3H),4.02(t,2H),4.20(d,1H),4.24(t,2H),4.68(d,2H),5.85(s,2H);6.90(d,1H),6.99(t,1H),7.15(m,2H),7.42(d,1H),7.49(d,1H),7.56(m,1H),7.82(d,2H),8.42(dd,1H),8.55-9.28(bs,5H)。
实施例20 抗凝活性的评价
20.1 活化部分凝血活酶时间(aPTT)的测定
将质量18-20g的昆明小鼠,随机分组,每组10只,禁食过夜。将达比加群酯(Dabigatran Etexilate)及待测目标化合物悬浮或溶解于1%的羧甲基纤维素钠的水溶液中,配成1mg/ml的浓度,按10mg/kg的剂量(折合成达比加群计算)灌胃给药,半小时后通过心脏穿刺取血,加入4%枸橼酸钠溶液至0.4%终浓度抗凝,12000r/min离心5分钟,取血浆0.1ml,加入aPTT试剂(上海医用电子有限公司产品)0.1ml,37℃预温3分钟后,加入37℃预温的氯化钙溶液0.1mL,用血小板聚集凝血因子分析仪(普利生PLSC2000-4型)测定凝固时间,即为aPTT值。结果见表1。
表1活化部分凝血活酶时间(aPTT)的测定结果
20.2 出血时间的测定
将质量18-20g的昆明小鼠,随机分组,每组10只,禁食过夜。将达比加群酯(Dabigatran Etexilate)及待测目标化合物悬浮或溶解于1%的羧甲基纤维素钠的水溶液中,配成1mg/ml的浓度,按10mg/kg的剂量(折合成达比加群计算)灌胃给药,半小时后。将动物固定,使尾巴浸于37℃的生理盐水中2min,然后在距尾端2mm处切断鼠尾,立即重新浸入37℃的生理盐水中,以停止出血持续30秒为判断终点,测定出血时间。结果见表2。
表2出血时间(aPTT)的测定结果
Claims (6)
2.权利要求1的式I所代表的达比加群的酯衍生物或其可药用盐,其中R1代表C1-C5的烷基,R2代表H或C1-C3的烷基,R3代表C1-C8的烷基。
3.权利要求1的式I所代表的达比加群的酯衍生物或其可药用盐,其中R1代表C1-C5的烷基,R2代表H,R3代表α-位为氨基取代的C1-C8的烷基。
4.权利要求1所述的式I所代表的达比加群的酯衍生物或其可药用盐,选自如下结构式所代表的化合物:
其中,R1、R2及R3分别定义如下:
I4:R1为-CH3,R2为H,R3为-CH(CH3)2;
I11:R1为-CH3,R2为H,R3为-CH(NH2)CH3;
I12:R1为-CH3,R2为H,R3为-CH(NH2)CH2CH(CH3)2;
I13:R1为-CH3,R2为H,R3为-CH(NH2)CH(CH3)CH2CH3;
I14:R1为-CH3,R2为H,R3为-CH(NH2)CH(CH3)2;
I18:R1为-CH2CH3,R2为H,R3为-CH2CH3;
I19:R1为-CH2CH3,R2为H,R3为-CH2CH2CH3;
I20:R1为-CH2CH3,R2为H,R3为-CH(CH3)2;
I26:R1为-CH2CH3,R2为H,R3为-CH2NH2;
I27:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH3;
I28:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH2CH(CH3)2;
I29:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)CH2CH3;
I30:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)2;
I31:R1为-CH2CH3,R2为H,R3为-CH(NH2)CH2Ph;
I43:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH3;
I44:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH2CH(CH3)2;
I45:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)CH2CH3;
I46:R1为-CH2CH2CH3,R2为H,R3为-CH(NH2)CH(CH3)2;
I67:R1为-CH2CH3,R2为CH3,R3为-CH2CH2CH3。
5.药物组合物,其包括至少一种权利要求1-4任一项所述的达比加群的酯衍生物或其可药用盐,以及一种或多种药学上可接受的载体或赋形剂。
6.权利要求1-4任一项所述的达比加群的酯衍生物或其可药用盐,以及含有权利要求1-4任一项所述的达比加群的酯衍生物或其可药用盐作为活性成分的药物组合物在制备凝血酶抑制剂药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910211165.2A CN102050815B (zh) | 2009-11-06 | 2009-11-06 | 作为前药的达比加群的酯衍生物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910211165.2A CN102050815B (zh) | 2009-11-06 | 2009-11-06 | 作为前药的达比加群的酯衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102050815A CN102050815A (zh) | 2011-05-11 |
CN102050815B true CN102050815B (zh) | 2014-04-02 |
Family
ID=43955662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910211165.2A Expired - Fee Related CN102050815B (zh) | 2009-11-06 | 2009-11-06 | 作为前药的达比加群的酯衍生物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102050815B (zh) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102838588B (zh) * | 2011-06-24 | 2014-03-19 | 中国药科大学 | 一类可用于口服的凝血酶抑制剂、其制法以及医药用途 |
WO2013024394A1 (en) * | 2011-08-12 | 2013-02-21 | Alembic Pharmaceuticals Limited | Novel reference markers of dabigatran etexilate |
CN102993174A (zh) * | 2011-09-08 | 2013-03-27 | 天津药物研究院 | 作为前药的达比加群的酯衍生物 |
CN103420980A (zh) * | 2012-05-22 | 2013-12-04 | 北京美倍他药物研究有限公司 | 达比加群衍生物 |
CN104892574A (zh) | 2014-03-04 | 2015-09-09 | 浙江海正药业股份有限公司 | 达比加群酯甲磺酸盐的晶型及其制备方法和用途 |
CN111793058A (zh) * | 2019-04-09 | 2020-10-20 | 鲁南制药集团股份有限公司 | 一种制备达比加群酯中间体的改良方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037075A1 (de) * | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituierte bicyclische heterocyclen, ihre herstellung und ihre verwendung als arzneimittel |
CN1972919A (zh) * | 2004-06-25 | 2007-05-30 | 贝林格尔·英格海姆国际有限公司 | 制备4-(苯并咪唑基甲氨基)-苯甲脒的方法 |
WO2008095928A1 (en) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Process for the preparation of a benzimidazole derivative |
-
2009
- 2009-11-06 CN CN200910211165.2A patent/CN102050815B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037075A1 (de) * | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituierte bicyclische heterocyclen, ihre herstellung und ihre verwendung als arzneimittel |
CN1972919A (zh) * | 2004-06-25 | 2007-05-30 | 贝林格尔·英格海姆国际有限公司 | 制备4-(苯并咪唑基甲氨基)-苯甲脒的方法 |
WO2008095928A1 (en) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Process for the preparation of a benzimidazole derivative |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9403793B2 (en) | 2012-07-03 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
US9840472B2 (en) | 2013-12-07 | 2017-12-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of mucositis |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9988340B2 (en) | 2014-09-29 | 2018-06-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
Also Published As
Publication number | Publication date |
---|---|
CN102050815A (zh) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102050815B (zh) | 作为前药的达比加群的酯衍生物 | |
CN102050814B (zh) | 达比加群的酯衍生物 | |
JP2015518891A (ja) | 抗ウイルス化合物の固体形態 | |
CN102875529B (zh) | 达比加群的酯衍生物及其制备方法 | |
CN103420980A (zh) | 达比加群衍生物 | |
KR20150082633A (ko) | 경구적으로 생체이용가능한 신규 호흡 조절 제어 화합물 및 그의 사용 방법 | |
WO2016007046A1 (ru) | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты | |
CN101348463B (zh) | 阿加曲班及其中间体的合成方法 | |
CN106750250A (zh) | 以氨基酸作为连接臂的聚乙二醇齐墩果酸衍生物及其制备方法和应用 | |
CN106661060B (zh) | 菲罗啉膦酸类衍生物及其制备方法和应用 | |
CN109293660B (zh) | 吴茱萸次碱-no供体偶联物及其应用 | |
CN106905193A (zh) | 芳酰基胍基奥司他韦羧酸衍生物及其制备方法和应用 | |
CN103420985B (zh) | 作为前药的达比加群酯衍生物及其制备方法和用途 | |
CN106478764B (zh) | 丹参酮iia磷酸衍生物、及其合成和作为药物的应用 | |
CN102250099B (zh) | 一类非肽类抗凝血酶抑制剂、其制法以及医药用途 | |
CN103420984B (zh) | 作为前药的达比加群酯衍生物及其制备方法和用途 | |
CN103420983B (zh) | 达比加群酯衍生物及其制备方法和用途 | |
CN105960399B (zh) | 酶抑制剂环氧酮化合物 | |
CN107235974A (zh) | 具有药物活性的哌啶磺酰胺‑钙配合物的制备方法 | |
CN103435514B (zh) | 基质金属蛋白酶抑制剂及其用途 | |
CN102250127B (zh) | 两个氨基酸修饰的四氢咔啉衍生物及其制备方法和应用 | |
CN103420994B (zh) | 作为前药的达比加群酯衍生物及其制备方法和用途 | |
CN102993175B (zh) | 达比加群的酯衍生物及其制备方法和用途 | |
CN103420982B (zh) | 达比加群酯衍生物及其制备方法和用途 | |
CN101812025B (zh) | 吡嗪芳酸醚类化合物、制备方法和医药应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190201 Address after: 102628 Building 301, No. 30 Jinxing Road, Daxing District, Beijing Patentee after: Beijing Hongsheng Pharmaceutical Technology Co.,Ltd. Address before: Room 120-13, Building 2, 139 Fengtai Road, Fengtai District, Beijing 100070 Patentee before: BEIJING MEIBEITA DRUG RES Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140402 |